The benefits of trastuzumab in the treatment of human epidermal receptor 2-positive breast cancer as a function of exposure time
收藏Mendeley Data2026-04-09 收录
官方服务：
资源简介：
Shorter times of trastuzumab exposition (<1 year) could protect from disease progression in breast cancer patients. Survival analysis of continuous predictor was used to obtain optimal cut-offs regarding DMFS, DFS, and OS.
